Background and Purpose
Read about how SITS came to be!
SITS - Safe Implementation of Treatments in Stroke, is a non-profit, research-driven, independent, international collaboration. It’s an initiative by the medical profession to assure excellence in acute treatment and secondary prevention of stroke, as well as to facilitate clinical trials.
SITS started in 1996 as an initiative by participants in the European-Australian randomised stroke thrombolysis studies (ECASS). But it was not until 2002 it was given a broader international role. European Union authorities then requested that all patients treated with thrombolysis should be registered in SITS for a period of three years. Registration in SITS became a condition for approval of treatment with intravenous thrombolysis in the EU.
Also in 2002, the European Medicines Agency (then EMEA, currently EMA) endorsed SITS as the registry for follow-up on thrombolysis treatment in acute ischemic stroke.
SITS has since then developed its services to enable follow-up of other evidence based treatments in acute stroke such as thrombectomy, as well as secondary prevention.
Today, over 260 000 patient files are included from over 80 countries on five continents, which makes SITS a world-leading stroke network.
More than 80 scientific reports have been published in international peer-reviewed journals based on data from SITS.
“SITS is my favoured registry because it is truly international, which enables us to measure our standards against other countries. In addition, it is restricted to patients who receive certain interventions, so we can concentrate on the most relevant patients; and we can readily get reports to assess our performance on logistics and outcomes. A secondary advantage is that it has answered many scientific questions and has been an invaluable research tool.“ – K. Lees, United Kingdom